(secondQuint)Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma.

 OBJECTIVES: I.

 Determine the response rate to oxaliplatin in patients with relapsed or refractory non-Hodgkin's lymphoma.

 II.

 Determine the treatment-related toxicity of this drug in these patients.

 OUTLINE: This is a multicenter study.

 Patients are stratified according to histologic subtype (indolent vs aggressive).

 Patients receive oxaliplatin IV over 2 hours on day 1.

 Treatment repeats every 21 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.

 PROJECTED ACCRUAL: A maximum of 72 patients will be accrued for this study within 2-3 years.

.

 Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma@highlight

Phase II trial to study the effectiveness of oxaliplatin in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.

 Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die